NEW YORK, Aug. 8, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") AMPE resulting from allegations that Ampio and/or its executives may have issued materially misleading business information to the investing public.

If you purchased Ampio securities, and/or would like to discuss your legal rights and options, please visit Ampio Shareholder Investigation or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

On August 7, 2018, during aftermarket hours, Ampio filed a Form 8-K with the SEC providing a regulatory update of the FDA's review of Ampion, including the AP-003-A trial. Ampio stated that it "met with the FDA in July 2018 and have received a letter in response thereto." In the letter, "the FDA stated that…that as a single trial the AP-003-A study alone does not appear to provide sufficient evidence of effectiveness to support a BLA…[and] the FDA does not consider the AP-003-C trial to be an adequate and well-controlled clinical trial." Ampio stated that "[t]he FDA recommended that [it] perform an additional randomized trial with a concurrent control group and that [it] request a Special Protocol Assessment to obtain FDA concurrence of the trial design before beginning the study."

On this news, shares of Ampio fell sharply during intra-day trading on August 8, 2018.

If you purchased Ampio securities, and/or would like to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/ampio-pharmaceuticals-inc-ampe-lawsuit-class-action-fraud-stock-76/ or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information

Daniel Sadeh

Bernstein Liebhard LLP

http://www.bernlieb.com  

(877) 779-1414

dsadeh@bernlieb.com  

View original content with multimedia:http://www.prnewswire.com/news-releases/ampe-alert-bernstein-liebhard-llp-announces-investigation-of-ampio-pharmaceuticals-inc---ampe-300694112.html

SOURCE Bernstein Liebhard LLP